

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

UNITED THERAPEUTICS  
CORPORATION,

*Plaintiff,*

v.

LIQUIDIA TECHNOLOGIES, INC.,

*Defendant.*

C.A. No. 1:20-cv-00755-RGA



**EXPERT REPORT OF DR. IGOR GONDA**

## Table of Contents

	Page
I. INTRODUCTION .....	1
II. MATERIALS CONSIDERED .....	1
III. BACKGROUND AND QUALIFICATIONS .....	1
IV. LEGAL PRINCIPLES .....	3
A. Claim Construction .....	3
B. Level of Ordinary Skill in the Art .....	4
C. Obviousness .....	5
D. Anticipation .....	6
E. Written Description .....	6
F. Enablement .....	6
G. Indefiniteness .....	7
V. BACKGROUND TO THE ART .....	8
A. History of Inhalation Therapy .....	8
B. Inhaled Treprostinil and Its Analogues .....	10
C. Well Known Considerations for Inhalation Therapies .....	12
VI. '793 PATENT .....	16
A. The Specification .....	16
B. The Claims of the '793 Patent .....	17
VII. SUMMARY OF OPINIONS .....	18
VIII. SUMMARY OF PRIOR ART .....	19
A. '212 Patent .....	19
B. Voswinckel JESC .....	21
C. Voswinckel JAHA .....	22
D. Voswinckel 2006 .....	24
IX. APPLICATION OF THE PRIOR ART TO THE CLAIMS .....	24
A. Claims 1, 4, and 6-8 Are Obvious Over '212 Patent in Combination with Voswinckel JESC and Voswinckel JAHA .....	25
B. Claims 1-8 Are Obvious Over '212 Patent in Combination with Voswinckel JESC .....	29
C. Claims 1 and 8 Are Rendered Obvious by Voswinckel JAHA in Combination with Ghofrani .....	29

D.	Claims 4 and 6-8 Are Obvious Over Voswinckel 2006 in Combination with the '212 Patent .....	30
E.	Objective Evidence of Non-Obviousness .....	34
X.	THE DISCLOSURE OF THE '793 PATENT IS INSUFFICIENT .....	35
A.	A POSA Would Not Understand That the '793 Patent Inventors Were in Possession of a Treprostinil Powder Formulation of Suitable for Administration in a Dry Powder Inhaler.....	35
XI.	THE ASSERTED '793 PATENT CLAIMS ARE NOT ENABLED.....	40
A.	The Specification of the '793 Patent Does Not Enable a Powder Formulation of Treprostinil or its Salt .....	40
XII.	RESERVATION OF RIGHTS .....	61

..

## I. INTRODUCTION

1. My name is Igor Gonda and I have been retained by Liquidia Technologies Inc. (“Liquidia”) as an expert in *United Therapeutics Corporation v. Liquidia Technologies Inc.*, Case No. 1:20-cv-00755-RGA in the District of Delaware.

2. I reserve the right to prepare exhibits to summarize and demonstrate my testimony at trial.

3. I have not testified as an expert in the past 4 years.

4. I was paid my customary rate of \$850 per hour for my study of this matter and for any time I might spend testifying. My compensation is in no way dependent on the outcome of the case.

## II. MATERIALS CONSIDERED

5. In forming my opinions, I have considered the materials specifically cited in my report as well as the documents identified in **Attachment B**.<sup>1</sup>

## III. BACKGROUND AND QUALIFICATIONS

6. I am currently the founder and CEO of Respidex LLC, which has offered consulting services to pharmaceutical and medical device companies since 2018. Before founding Respidex LLC, I held leadership positions at several pharmaceutical companies, including Aradigm Corporation, a company that focused on developing inhalation therapies for the prevention and treatment of serious respiratory and systemic diseases.

7. In 1971, I received my Bachelor of Science in Chemistry from the University of Leeds. In 1974, I received my Ph.D. in Physical Chemistry from the University of Leeds. After

---

<sup>1</sup> I understand that counsel for UTC has not yet permitted Liquidia to take the deposition of Dr. Robert Roscigno, a named inventor on the '793 patent, and also a corporate deposition concerning the conception and reduction to practice of the invention claimed in the '793 patent. I reserve the right to supplement my expert reports, if needed, to consider this information.



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.